[
  {
    "question": "LL cramps in beginning of exercise, improve with rest, test to Dx",
    "option_a": "(MRI) is not useful for assessing metabolic function and is intended for structural abnormalities. Option B (ischemic forearm test) is correct because it assesses lactate production, the gold standard for diagnosing glycolytic defects. Option C (Nerve conduction studies) evaluates nerve function, not muscle metabolism. Option D (Serum CK) is non",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Exercise\u2010induced cramps that improve with rest are classic for metabolic myopathies such as glycogen storage disorders (e.g., McArdle disease). The ischemic forearm test is used to functionally assess muscle glycolytic capacity by measuring lactate production during exercise under ischemic conditions. In conditions like McArdle disease, a deficiency of muscle phosphorylase prevents adequate glycogen breakdown, leading to insufficient anaerobic energy production during exercise. The inability to raise lactate levels during ischemia results in muscle cramping and early fatigue. Patients typically present with lower limb cramps and exercise intolerance that improve with rest. The key diagnostic feature is a blunted or absent rise in lactate after the ischemic forearm test, directly indicating impaired glycolytic function. Differential diagnoses include other forms of metabolic myopathy, neuromuscular junction disorders, and peripheral neuropathies. Beyond the ischemic forearm test, other evaluations may include serum CK (which might be normal or slightly elevated) and EMG, but these are not specific. Muscle biopsy and genetic testing can also be considered for confirmation. Management is primarily supportive and involves lifestyle modifications such as graded exercise programs and avoiding strenuous activities that trigger symptoms. Dietary modifications, including pre-exercise carbohydrate intake, may help. In pregnancy and lactation, exercise should be moderated and nutritional support optimized, while avoiding undue muscle strain. Genetic counseling is advised for family planning. Option A (MRI) is not useful for assessing metabolic function and is intended for structural abnormalities. Option B (ischemic forearm test) is correct because it assesses lactate production, the gold standard for diagnosing glycolytic defects. Option C (Nerve conduction studies) evaluates nerve function, not muscle metabolism. Option D (Serum CK) is non-specific and may be normal in metabolic myopathies. 1. The ischemic forearm test is a key, cost-effective test in evaluating suspected metabolic myopathies. 2. McArdle disease typically presents with exercise-induced cramps that rapidly improve with rest. Recent research and clinical guidelines continue to validate the ischemic forearm test's role in diagnosing glycogen storage diseases, although genetic testing is emerging as an important confirmatory tool.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Weakness induced by cold",
    "option_a": "(Na channel) is associated with disorders like paramyotonia congenita, not classic cold",
    "option_b": "(K channel) relates to periodic paralyses linked to potassium abnormalities. Option C (Ca channel) is implicated in conditions such as malignant hyperthermia rather than cold",
    "option_c": "",
    "option_d": "(Cl channel) is correct because ClC",
    "option_e": "",
    "correct_answer": "D",
    "subspecialty": "Neuromuscular",
    "explanation": "Cold-induced muscle weakness is most commonly associated with myotonia congenita, a disorder of skeletal muscle chloride channels. These channels are pivotal in stabilizing the resting membrane potential and ensuring proper muscle relaxation. Mutations in the CLCN1 gene reduce chloride conductance, leading to membrane hyperexcitability and delayed muscle relaxation (myotonia). Exposure to cold can further slow the kinetics of these chloride channels, exacerbating the weakness and stiffness. Clinically, affected patients experience muscle stiffness and impaired contraction that worsens with cold exposure. This distinct pattern helps differentiate myotonia congenita from other channelopathies associated with sodium, potassium, or calcium channels. The workup involves electromyography (EMG), which typically shows myotonic discharges. Genetic testing for CLCN1 mutations confirms the diagnosis. Differential diagnoses include paramyotonia congenita (typically due to sodium channel mutations), hypokalemic periodic paralysis (potassium channel related), and calcium channelopathies seen in malignant hyperthermia. First-line management includes conservative measures like avoiding cold exposure and using medications such as mexiletine to reduce myotonia. In pregnant or lactating patients, drug safety is paramount; for instance, mexiletine\u2019s use is cautious during pregnancy and lactation due to potential fetal/neonatal effects, so alternative management may be considered. Option A (Na channel) is associated with disorders like paramyotonia congenita, not classic cold-induced weakness. Option B (K channel) relates to periodic paralyses linked to potassium abnormalities. Option C (Ca channel) is implicated in conditions such as malignant hyperthermia rather than cold-induced weakness. Option D (Cl channel) is correct because ClC-1 mutations directly cause myotonia congenita with cold sensitivity. 1. Myotonia congenita due to ClC-1 mutations is classically worsened by cold, making environmental modification a key management factor. 2. EMG and genetic testing are definitive diagnostic tools in distinguishing chloride channel disorders from other channelopathies. Emerging studies continue to clarify the biophysical properties of ClC-1 channels and their modulation by temperature, supporting targeted therapeutic strategies and reinforcing the importance of genetic diagnosis in guiding management.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Case of muscle weakness with Deltoid sparing?",
    "option_a": "(Myotonic dystrophy type 2) is correct as it is known for proximal muscle weakness with deltoid sparing. Option B (Facioscapulohumeral dystrophy) typically exhibits weakness in the deltoid and facial muscles, making it inconsistent with the clinical presentation.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Muscle weakness with a pattern of deltoid sparing is a distinguishing feature in certain muscular dystrophies. Myotonic dystrophy type 2 (DM2) typically involves proximal muscle weakness while often sparing the deltoids, aiding in its clinical differentiation. DM2 is caused by a CCTG repeat expansion in the CNBP gene, leading to multisystemic manifestations including myotonia, muscle weakness, and other systemic features. The selective muscle involvement, including deltoid sparing, is due to the variable susceptibility of different muscle groups. Patients with DM2 present with proximal muscle weakness, myotonia, and sometimes systemic involvement such as cataracts, insulin resistance, and endocrine abnormalities. The preservation of deltoid strength is an important clinical clue that differentiates DM2 from other muscular dystrophies like facioscapulohumeral dystrophy, which often involves the deltoid. The diagnosis is confirmed with genetic testing to identify the CCTG repeat expansion. Differential diagnoses include other forms of muscular dystrophy, particularly FSHD which typically affects the deltoid and facial muscles. Muscle biopsy and EMG may provide supportive evidence. Management of DM2 is supportive and multidisciplinary, focusing on symptom control with physical therapy, management of myotonia, and surveillance for systemic complications (cardiac, endocrine, etc.). In pregnancy, close monitoring is necessary due to potential complications, and lactation management remains supportive, ensuring both maternal and infant safety. Option A (Myotonic dystrophy type 2) is correct as it is known for proximal muscle weakness with deltoid sparing. Option B (Facioscapulohumeral dystrophy) typically exhibits weakness in the deltoid and facial muscles, making it inconsistent with the clinical presentation. 1. Deltoid sparing is a key sign in DM2 that differentiates it from other muscular dystrophies. 2. Genetic testing is essential for a definitive diagnosis and appropriate management decisions. Recent guidelines stress the importance of a multidisciplinary approach in managing DM2, emphasizing early cardiac screening and endocrine evaluation to mitigate systemic complications associated with the disease.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Post vaginal delivery with eclampsia, had progressive flaccid paralysis, next step",
    "option_a": "(Mg level) is correct because serum magnesium measurement is the immediate test to confirm toxicity. Option B (Nerve conduction studies) are not practical in the acute setting. Option C (Ca level) does not address the primary problem. Option D (MRI) is inappropriate for diagnosing a metabolic/neurotoxicity issue.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "In the postpartum period following treatment of eclampsia with magnesium sulfate, the development of progressive flaccid paralysis is highly suggestive of magnesium toxicity. This toxicity results from supratherapeutic levels of magnesium leading to neuromuscular blockade. Magnesium acts by inhibiting acetylcholine release at the neuromuscular junction. Excess magnesium, as seen in toxicity, causes a decrease in neuromuscular transmission, leading to progressive weakness, loss of deep tendon reflexes, and potential respiratory compromise. Clinically, a postpartum patient who develops flaccid paralysis after receiving magnesium sulfate should prompt immediate concern for magnesium toxicity. The timing and progression of weakness, along with a history of magnesium administration for eclampsia, are critical in raising the suspicion. The most expedient and direct method to evaluate suspected magnesium toxicity is to check the serum magnesium level. Other differential diagnoses such as Guillain-Barr\u00e9 syndrome or myasthenia gravis are less likely in the acute postpartum setting with recent magnesium administration. First-line management includes discontinuation of the magnesium sulfate infusion and immediate measurement of serum magnesium levels. Supportive care with respiratory monitoring and, if indicated, administration of intravenous calcium gluconate (an antidote for magnesium toxicity) is recommended. In pregnancy and postpartum care, careful dosing and monitoring of magnesium are critical, while lactation is generally not adversely affected but requires supportive management. Option A (Mg level) is correct because serum magnesium measurement is the immediate test to confirm toxicity. Option B (Nerve conduction studies) are not practical in the acute setting. Option C (Ca level) does not address the primary problem. Option D (MRI) is inappropriate for diagnosing a metabolic/neurotoxicity issue. 1. Always monitor deep tendon reflexes and respiratory status in patients receiving magnesium sulfate. 2. Magnesium toxicity should be suspected when flaccid paralysis occurs in the postpartum period after magnesium therapy. Recent obstetric guidelines underscore the need for vigilant monitoring of magnesium levels during therapy for eclampsia, with recommendations for dosage adjustments to prevent toxicity and associated neuromuscular complications.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Case: dysarthria and dysphagia, with the attached picture. What you expect to find on this patient",
    "option_a": "(Left eye ptosis) is incorrect because the clinical details and image indicate the weakness is on the right side. Option b (Right eye ptosis) is correct as it accurately reflects the neuromuscular involvement in MG, particularly given the symptoms of dysarthria and dysphagia, which support bulbar involvement. Option c (Right plantar Babinski response) is incorrect because the Babinski sign is indicative of an upper motor neuron lesion, not a neuromuscular junction disorder.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Neuromuscular",
    "explanation": "This case centers on a neuromuscular junction disorder such as Myasthenia Gravis (MG), which is classically associated with fluctuating muscle weakness. The core concept involves an immune-mediated attack on the postsynaptic acetylcholine receptors, leading to impaired neuromuscular transmission. In MG, autoantibodies (most commonly anti-acetylcholine receptor antibodies) bind to receptors at the neuromuscular junction, leading to receptor degradation and complement-mediated damage. This results in reduced neuromuscular transmission efficiency. Bulbar muscles (involved in speech and swallowing) and ocular muscles (leading to ptosis) are frequently affected, making signs like dysarthria, dysphagia, and ptosis key clinical features. Patients with MG typically present with fatigable weakness. Ocular symptoms like ptosis (drooping of the eyelid) are seen early and can be unilateral or bilateral. Dysarthria and dysphagia indicate bulbar involvement. The provided image and clinical description point towards right eye involvement; hence, finding right eye ptosis (Option b) is most consistent with the diagnosis. Diagnosis hinges on clinical suspicion supplemented by antibody testing (anti-AChR or MuSK antibodies), repetitive nerve stimulation studies, and the ice pack test. Differential diagnoses include Lambert-Eaton Myasthenic Syndrome (associated with malignancy and proximal muscle weakness without typical ocular signs) and brainstem stroke (which would present with additional central neurological deficits such as pyramidal signs). First-line therapy includes acetylcholinesterase inhibitors (e.g., pyridostigmine) to improve neuromuscular transmission. Immunosuppressive agents (such as prednisone, azathioprine) are used for long-term management. Rapid therapies like plasmapheresis or IVIG are reserved for myasthenic crisis. In pregnancy, pyridostigmine is generally considered safe, though immunosuppressants require risk\u2013benefit analysis; consultation with neurology and obstetrics is essential. Lactating mothers should use medications with a known safety profile or minimal breast milk transfer. Option a (Left eye ptosis) is incorrect because the clinical details and image indicate the weakness is on the right side. Option b (Right eye ptosis) is correct as it accurately reflects the neuromuscular involvement in MG, particularly given the symptoms of dysarthria and dysphagia, which support bulbar involvement. Option c (Right plantar Babinski response) is incorrect because the Babinski sign is indicative of an upper motor neuron lesion, not a neuromuscular junction disorder. 1. Fluctuating weakness with ocular and bulbar involvement is hallmark for MG. 2. Ptosis is an early and common sign in MG. 3. A Babinski sign points away from a neuromuscular junction disorder and toward a central nervous system pathology. Recent guidelines underscore the importance of antibody testing for diagnosis and highlight individualized immunosuppressive regimens. There is also emerging data regarding newer biologics (e.g., eculizumab) for refractory cases, though their use must be carefully balanced against safety profiles, especially regarding pregnancy and lactation.",
    "exam_year": "2019",
    "exam_type": "Part I",
    "image_url": "page_3.png"
  },
  {
    "question": "Case with stiffness induced by exercise, sneezing induce forcefully eye closure & percussion myotonia and eyelid myotonia",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "d",
    "subspecialty": "Neuromuscular",
    "explanation": "This case describes a classic presentation of myotonia, where muscle stiffness and delayed relaxation are triggered by exercise and other stimuli like forced eye closure. Myotonia congenita is primarily a muscle membrane disorder due to channel dysfunction. Myotonia congenita is most commonly caused by mutations in the CLCN1 gene encoding the skeletal muscle chloride channel (ClC-1). This channel is essential for stabilizing the resting membrane potential. Its dysfunction results in hyperexcitability of the muscle membrane, leading to prolonged contraction after voluntary movement or percussion (myotonia). Patients typically exhibit exercise-induced stiffness, percussion myotonia (elicited by tapping the muscle), and eyelid myotonia (manifesting as difficulty in relaxing the eyelids following forceful closure). These signs are highly suggestive of a chloride channelopathy. Diagnosis is based on clinical findings, electromyography (EMG) that reveals characteristic myotonic discharges, and confirmed by genetic testing for CLCN1 mutations. Differential diagnoses include paramyotonia congenita (linked to sodium channel mutations, often with cold sensitivity and episodic weakness), Andersen-Tawil syndrome (potassium channel mutations, with periodic paralysis and dysmorphic features), and other sodium channel myotonias. Management is largely symptomatic. First-line therapies include mexiletine, a sodium channel blocker that can help reduce myotonic stiffness by stabilizing the membrane. Other options include lifestyle modifications and avoidance of triggers. In pregnancy, mexiletine is usually avoided due to limited safety data, and treatment modifications under specialist guidance are warranted. Lactation considerations also require using medications with documented safety profiles in nursing mothers. Option (d) is correct because chloride channel dysfunction is the classical etiology for myotonia congenita. Option (a) (Na channel) is incorrect as sodium channel mutations are more typically associated with paramyotonia congenita. Option (b) (K channel) and option (c) (Ca channel) are incorrect as they are linked with other distinct neuromuscular disorders (Andersen-Tawil syndrome and hypokalemic periodic paralysis respectively) that do not primarily present with percussion or eyelid myotonia. 1. Myotonia congenita typically features exercise-induced stiffness and myotonic phenomena on examination. 2. The presence of eyelid myotonia is a key diagnostic clue. 3. EMG studies are vital for confirming the diagnosis via myotonic discharges. Current guidelines support the use of mexiletine for symptomatic relief in myotonia congenita. Ongoing research focuses on alternative ion channel modulators that might offer effective symptom control with fewer side effects. Additionally, genetic counseling is recommended for affected families.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Congenital MG with distal and proximal weakness, facial involvement worsened with Ach-esterase inhibitor",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "This scenario involves a congenital myasthenic syndrome (CMS), a group of inherited disorders affecting the neuromuscular junction. The key conceptual point here is that not all CMS subtypes respond to acetylcholinesterase inhibitors; in fact, some worsen with their use. DOK7 mutations impair the activation of MuSK (muscle-specific kinase), which is critical for the clustering of acetylcholine receptors at the neuromuscular junction. Reduced receptor clustering leads to diminished signal transmission across the junction. Paradoxically, the use of acetylcholinesterase inhibitors may exacerbate symptoms in DOK7-related CMS, as increasing acetylcholine concentration does not compensate for the defective receptor clustering and may worsen depolarization. Patients with DOK7 CMS typically present with both proximal and distal muscle weakness along with facial involvement. The worsening of symptoms with acetylcholinesterase inhibitors is a distinctive clue, differentiating it from other forms of CMS where these inhibitors improve symptoms. Diagnosis relies on clinical history, response to acetylcholinesterase inhibitors (or the lack thereof, even worsening), EMG studies, and genetic testing. Differential diagnoses include CMS due to RAPSN or CHRNE mutations, which generally respond to acetylcholinesterase inhibitors, and fast-channel CMS where the response profile is variable. The first-line treatment for DOK7 CMS is beta-2 adrenergic agonists (e.g., salbutamol/albuterol), which have been shown to improve muscle strength. Acetylcholinesterase inhibitors are typically avoided. In pregnancy, beta-2 agonists are generally considered relatively safe but should be used under close supervision. Similarly, lactating women should use these agents with caution and under medical guidance. Option (a) DOK7 is correct because it explains the clinical picture where acetylcholinesterase inhibitors worsen symptoms due to impaired MuSK signaling. Option (b) RAPSN, option (c) CHRNE, and option (d) FCMS are less likely because they either improve with acetylcholinesterase inhibitors or present with different clinical profiles. 1. Not all CMS subtypes respond favorably to standard acetylcholinesterase inhibitor therapy. 2. DOK7-related CMS is characterized by paradoxical worsening with these agents. 3. Beta-2 agonists are the treatment of choice in DOK7 CMS. Recent studies support the efficacy of beta-2 agonists in DOK7-related CMS and caution against the use of acetylcholinesterase inhibitors in such cases. Genetic testing has become the diagnostic standard, guiding specific therapy and prognosis.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "A 57-year-old male referred to neurology consultation from gastro team, he has complaint of dysphagia with negative GI workup, he found to have wrist flexion and knee extension weakness. CK was 700. What is your diagnosis?",
    "option_a": "",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Neuromuscular",
    "explanation": "This case involves a patient with muscle weakness and dysphagia, where the distribution of muscle involvement is crucial for diagnosis. Inclusion Body Myositis (IBM) is characterized by both proximal and distal muscle involvement, particularly affecting wrist flexors and knee extensors, and is often seen in older males. IBM is an inflammatory myopathy with degenerative features. It is characterized by endomysial inflammation, rimmed vacuoles, and amyloid deposits within muscle fibers. The pathogenesis is thought to involve both autoimmune and degenerative mechanisms that lead to muscle fiber damage. Clinically, IBM typically presents in patients over the age of 50 with slowly progressive weakness. The pattern of weakness\u2014especially the involvement of the wrist flexors, quadriceps (knee extensors), and dysphagia\u2014is characteristic. CK levels are usually moderately elevated but not as high as in acute inflammatory myopathies. The diagnostic work-up includes muscle strength assessment, serum creatine kinase measurement, electromyography (EMG), and ultimately a muscle biopsy showing endomysial inflammation and rimmed vacuoles. Differential diagnoses include polymyositis (which usually presents with symmetric proximal weakness without significant distal involvement), dermatomyositis (which has characteristic skin findings), and facioscapulohumeral muscular dystrophy (FSHD; which primarily affects facial and shoulder muscles rather than distal weakness). There is no effective immunosuppressive treatment for IBM; management is mainly supportive, focusing on physical therapy, assistive devices, and nutritional support due to dysphagia. Current research is exploring potential agents (e.g., monoclonal antibodies) with limited success. In pregnancy and lactation\u2014although IBM is rare in women of childbearing age\u2014the management remains supportive, and immunosuppressive therapies (if trialed in atypical cases) require careful evaluation of fetal risk versus benefit. Option (a) Dermatomyositis is incorrect because it usually presents with proximal muscle weakness accompanied by characteristic skin rashes (e.g., heliotrope rash, Gottron\u2019s papules). Option (b) IBM is correct as it matches the clinical profile of an older male with distal (wrist flexor) and quadriceps involvement along with dysphagia and a modest CK elevation. Option (c) Polymyositis is incorrect because it typically involves symmetric proximal weakness without the prominent distal involvement and dysphagia seen in IBM. Option (d) FSHD is incorrect because it characteristically affects facial and shoulder girdle muscles, sparing the distal muscles such as wrist flexors, and dysphagia is not common. 1. IBM should be suspected in older males with combined proximal and distal muscle weakness, particularly involving the wrist flexors and quadriceps. 2. Dysphagia is a common and problematic symptom in IBM. 3. Muscle biopsy is the gold standard for diagnosing IBM. Recent research has reinforced the distinct clinicopathological features of IBM compared to other inflammatory myopathies. Trials for immunomodulatory therapy have not shown significant benefit in IBM, emphasizing the need for supportive care and ongoing investigation into disease-modifying treatments.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Steroid myopathy, due to atrophy of",
    "option_a": "(Type IIa fibers) is incorrect because these fibers, though fast",
    "option_b": "(Type IIb fibers) is correct as they are the most vulnerable. Option c (Type I fibers) is incorrect since these fibers are more oxidative and resistant to glucocorticoid",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Neuromuscular",
    "explanation": "Steroid myopathy is a drug\u2010induced myopathy that develops with prolonged glucocorticoid exposure, leading to proximal muscle weakness. The condition is characterized by the selective atrophy of fast-twitch muscle fibers, particularly type IIb fibers. Glucocorticoids exert catabolic effects by decreasing protein synthesis and increasing protein degradation via activation of the ubiquitin\u2013proteasome pathway. Type IIb fibers are especially vulnerable due to their metabolic profile and higher density of glucocorticoid receptors, leading to preferential atrophy. Patients on chronic corticosteroids typically present with insidious onset of proximal muscle weakness\u2014more evident in the shoulders and hips. The preservation of type I fibers means that endurance and low-intensity activities are less affected, while rapid, forceful contractions are compromised. Diagnosis is based on the clinical history of prolonged steroid use, characteristic clinical findings, and muscle biopsy showing selective atrophy of type IIb fibers. Differential diagnoses include inflammatory myopathies (e.g., polymyositis) that usually have elevated muscle enzymes and distinctive inflammatory infiltrates, and metabolic myopathies, which present with different biopsy findings. The primary approach is to reduce or discontinue corticosteroids if clinically feasible, often substituting with steroid-sparing agents. Supportive care with physical therapy is recommended to restore muscle strength. In pregnant and lactating patients, minimizing steroid exposure is crucial due to potential maternal myopathy and possible fetal effects, which may require dose adjustments and multidisciplinary monitoring. Option a (Type IIa fibers) is incorrect because these fibers, though fast-twitch, are less susceptible to steroid-induced atrophy than type IIb fibers. Option b (Type IIb fibers) is correct as they are the most vulnerable. Option c (Type I fibers) is incorrect since these fibers are more oxidative and resistant to glucocorticoid-induced catabolism. 1. Always suspect steroid myopathy in patients on long-term glucocorticoids who complain of proximal weakness without significant pain or high CK levels. 2. Reduction of steroid dose frequently leads to improvement in muscle strength over time. Recent studies reinforce the role of the ubiquitin\u2013proteasome system in steroid-induced muscle atrophy. Newer research is focused on steroid-sparing treatment protocols and molecular approaches that may protect muscle tissue during necessary corticosteroid therapy.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Hx of HCV with peripheral neuropathy",
    "option_a": "(Cryoglobulinemia) is correct as it directly links HCV with immune complex",
    "option_b": "(Anti",
    "option_c": "(GM1 antibody) is incorrect as it is more often implicated in multifocal motor neuropathy or certain Guillain",
    "option_d": "",
    "option_e": "",
    "correct_answer": "B",
    "subspecialty": "Neuromuscular",
    "explanation": "Chronic hepatitis C (HCV) infection is well-known for extrahepatic manifestations, including mixed cryoglobulinemia, an immune complex-mediated vasculitis that can affect peripheral nerves. In HCV-related cryoglobulinemia, circulating immune complexes (cryoglobulins) precipitate at lower temperatures and deposit in small vessels, including the vasa nervorum. This deposition leads to complement activation, vascular inflammation, and ischemic damage to peripheral nerves. Patients with HCV may develop peripheral neuropathy associated with vasculitic features such as palpable purpura, arthralgias, and other systemic symptoms. The neuropathy often presents with pain, sensory deficits, and sometimes motor involvement. Workup includes serological testing for HCV, quantification of cryoglobulins, assessment of complement levels, and nerve conduction studies to characterize neuropathy. Differential diagnoses include other causes of vasculitic neuropathy (e.g., lupus, rheumatoid vasculitis) which can be differentiated by serology and clinical context. Management hinges on treating the underlying HCV infection with direct-acting antivirals (DAAs), which can reduce cryoglobulin production. Immunosuppressive agents such as corticosteroids or rituximab may be indicated in severe cases of vasculitis. In pregnant and lactating women, careful consideration is needed when using immunosuppressants; corticosteroids can be used with caution and antiviral regimens may require modification to ensure fetal safety. Option a (Cryoglobulinemia) is correct as it directly links HCV with immune complex-mediated small-vessel vasculitis causing neuropathy. Option b (Anti-MAG neuropathy) is incorrect because it is typically associated with IgM monoclonal gammopathy rather than HCV. Option c (GM1 antibody) is incorrect as it is more often implicated in multifocal motor neuropathy or certain Guillain-Barr\u00e9 syndrome variants and is not linked to HCV. 1. Always screen for cryoglobulinemia in HCV patients presenting with neuropathic symptoms. 2. Early antiviral therapy can not only treat HCV but also help mitigate cryoglobulin-related complications. Recent guidelines emphasize the importance of early diagnosis and treatment of HCV with DAAs, which have been shown to reduce cryoglobulin levels. Additionally, emerging therapies such as rituximab are being supported by evidence in refractory cryoglobulinemic vasculitis.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Dermatomyositis:",
    "option_a": "(Rimmed vacuoles) is incorrect because rimmed vacuoles are a hallmark of inclusion body myositis, not dermatomyositis. Option b (Perifascicular inflammation) is correct and is the key histopathologic finding that supports a diagnosis of dermatomyositis.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "b",
    "subspecialty": "Neuromuscular",
    "explanation": "Dermatomyositis is an idiopathic inflammatory myopathy that presents with characteristic skin manifestations, such as a heliotrope rash and Gottron\u2019s papules, alongside proximal muscle weakness. The underlying mechanism involves complement-mediated injury to the endomysial capillaries, leading to perifascicular ischemia. Histologically, there is a predominantly perivascular and perifascicular inflammatory infiltrate mainly composed of CD4+ T cells and B cells, which distinguishes it from other myopathies. Patients typically have symmetric proximal muscle weakness with distinctive skin findings. Muscle biopsy reveals perifascicular atrophy and perivascular inflammation, reflecting the vascular damage that contributes to muscle fiber ischemia. Diagnosis is supported by clinical evaluation, laboratory evidence of muscle injury (e.g., elevated creatine kinase), electromyography, and confirmatory muscle biopsy showing perifascicular inflammation. Differential diagnoses include polymyositis (which lacks skin involvement) and inclusion body myositis (characterized by rimmed vacuoles and a different inflammatory pattern). First-line treatment is high-dose corticosteroids. Immunosuppressive agents such as methotrexate or azathioprine serve as steroid-sparing agents in refractory cases. In pregnant and lactating patients, corticosteroids are generally considered safe but require careful dose management to minimize potential risks, with continuous monitoring by multidisciplinary teams. Option a (Rimmed vacuoles) is incorrect because rimmed vacuoles are a hallmark of inclusion body myositis, not dermatomyositis. Option b (Perifascicular inflammation) is correct and is the key histopathologic finding that supports a diagnosis of dermatomyositis. 1. The presence of characteristic skin changes along with proximal muscle weakness is highly suggestive of dermatomyositis. 2. Muscle biopsy showing perifascicular inflammation is essential in differentiating dermatomyositis from other inflammatory myopathies. Recent guidelines advocate early, aggressive immunosuppressive therapy for dermatomyositis to prevent long-term muscle damage. Ongoing research is investigating the role of biologic therapies, especially in special populations such as pregnant or lactating women, to provide safer and effective alternatives.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "30 years male with severe demyelinating neuropathy, palpable nerve, biopsy: onion bulb, elevated CSF protein; in patient above. NCS: demyelinating features",
    "option_a": "(CMT1) is correct given the combination of demyelinating features on NCS, onion",
    "option_b": "(CMT2) is incorrect because it is characterized primarily by axonal degeneration without onion",
    "option_c": "(CMT3) typically presents in infancy with a more severe phenotype, and Option d (CMTX) has a different clinical spectrum and inheritance pattern.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Charcot-Marie-Tooth disease type 1 (CMT1) is a hereditary demyelinating neuropathy that typically manifests with progressive distal weakness, sensory loss, and characteristic nerve enlargement. CMT1 is caused by mutations affecting genes essential for myelin integrity (e.g., PMP22 in CMT1A). The demyelinating process, followed by repeated cycles of demyelination and remyelination, produces characteristic onion-bulb formations on nerve biopsy. An elevated CSF protein can be a secondary finding due to disruption of the blood\u2013nerve barrier. Clinically, patients present with slowly progressive distal muscle weakness, foot deformities (such as pes cavus), and sensory deficits. Palpable nerve hypertrophy is classic, and nerve conduction studies reveal significantly slowed velocities consistent with demyelination. The diagnosis is based on clinical history, family history, nerve conduction studies demonstrating demyelination, and nerve biopsy showing onion-bulb formations. Differential diagnoses include CMT2 (an axonal neuropathy without onion bulbs), CMT3 (Dejerine-Sottas disease which presents in childhood), and CMTX (which may have mixed features and distinct inheritance patterns). Management is mainly supportive and includes physical therapy, orthotic devices, and sometimes surgical intervention to correct foot deformities. Genetic counseling is important. In the context of pregnancy and lactation, supportive therapies and careful monitoring are essential to maintain mobility and function without exposing the fetus or infant to unnecessary risks. Option a (CMT1) is correct given the combination of demyelinating features on NCS, onion-bulb formations on biopsy, palpable nerve enlargement, and elevated CSF protein. Option b (CMT2) is incorrect because it is characterized primarily by axonal degeneration without onion-bulb formation. Option c (CMT3) typically presents in infancy with a more severe phenotype, and Option d (CMTX) has a different clinical spectrum and inheritance pattern. 1. Onion-bulb formation is indicative of chronic demyelination and remyelination cycles in CMT1. 2. Slowed conduction velocities on nerve studies help differentiate demyelinating neuropathies like CMT1 from axonal forms. Advances in molecular genetics have improved the diagnostic accuracy and classification of CMT subtypes. Current management guidelines emphasize multidisciplinary supportive care. Research into gene therapies is ongoing, with the potential to alter the disease course in the future.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "48-Male with toe walking, weakness, NL parents (cousin), 1 sister affected (all except):",
    "option_a": "(Calpainopathy) is consistent with LGMD R1 and fits the clinical picture. Option b (Dysferlinopathy) is also a recognized autosomal recessive LGMD subtype. Option c (Lamininopathy) is atypical for an LGMD presentation because laminin defects usually cause congenital muscular dystrophies with early onset. Option d (Sarco",
    "option_b": "",
    "option_c": "the correct answer even though the marked answer was a.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Neuromuscular",
    "explanation": "Limb\u2010girdle muscular dystrophies (LGMDs) are a heterogeneous group of genetically inherited muscle disorders characterized by progressive weakness of the proximal muscles. Different subtypes are classified based on the mutated gene and mode of inheritance. In this clinical scenario, the patient\u2019s presentation of toe walking and proximal weakness combined with an autosomal recessive family history favors an LGMD subtype. However, lamininopathies (involving defects in laminin proteins such as LAMA2) usually present in infancy/early childhood as congenital muscular dystrophies rather than as adult\u2010onset LGMD. Calpainopathy (LGMD R1, due to CAPN3 mutations), dysferlinopathy (LGMD R2, due to DYSF mutations), and sarcoglycanopathies (LGMD R3-R6 due to sarcoglycan gene mutations) all lead to structural instability and degeneration of muscle fibers. Lamininopathies arise from abnormal laminin proteins critical for muscle basement membrane integrity; they are pathogenic in congenital muscular dystrophies, not the typical LGMD with onset in adolescence or adulthood. The patient\u2019s toe walking and proximal muscle weakness, along with an autosomal recessive inheritance pattern (affected sister, non\u2010consanguineous parents), fits well with calpainopathy, dysferlinopathy, and sarcoglycanopathy. In contrast, lamininopathy generally presents in infants with marked hypotonia or congenital contractures rather than a toe-walking adolescent or adult. Evaluation involves serum creatine kinase (CK) measurement (often markedly elevated), electromyography, and ultimately confirmation with muscle biopsy and genetic testing. Differential diagnoses include other muscular dystrophies (such as Duchenne or Becker) and congenital myopathies. The age of onset, distribution of weakness, and inheritance pattern help narrow the diagnosis. There is no curative treatment for LGMD; management is therefore supportive, including physical therapy to maintain mobility, orthopedic interventions for contractures, and cardiac monitoring in subtypes with cardiac involvement. Genetic counseling is recommended. In pregnancy and lactation, multidisciplinary management is essential, and medications (when used) must be chosen with safety profiles in mind, although treatment is largely supportive rather than pharmacologic. Option a (Calpainopathy) is consistent with LGMD R1 and fits the clinical picture. Option b (Dysferlinopathy) is also a recognized autosomal recessive LGMD subtype. Option c (Lamininopathy) is atypical for an LGMD presentation because laminin defects usually cause congenital muscular dystrophies with early onset. Option d (Sarco-glycanopathy) represents another LGMD subgroup. Thus, among the choices, lamininopathy is the outlier, making option c the correct answer even though the marked answer was a. 1. LGMD subtypes share similar clinical features (proximal weakness) but differ in age of onset and extra-muscular involvement. 2. Lamininopathies are primarily congenital and are not typically grouped under LGMD syndromes. 3. A careful review of family history helps differentiate autosomal recessive from dominant forms. Recent consensus guidelines and the European Neuromuscular Centre (ENMC) update emphasize the importance of genetic testing to accurately classify LGMD subtypes, which is crucial for prognosis and potential gene-targeted therapies in the future.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "ttt of hypokalemic periodic paralysis",
    "option_a": "(Spironolactone) is a potassium",
    "option_b": "(Acetazolamide) helps prevent episodes but does not acutely reverse paralysis. Option c (Potassium) directly addresses the underlying hypokalemia, making it the correct treatment for an acute attack.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Neuromuscular",
    "explanation": "Hypokalemic periodic paralysis (HypoPP) is a channelopathy marked by episodes of flaccid paralysis due to a transient shift of potassium into cells. The core treatment goal during an attack is to quickly restore serum potassium levels. Defects in voltage-gated ion channels (most commonly calcium channels such as CACNA1S mutations) cause abnormal depolarization of muscle fibers. This leads to an excessive intracellular shift of potassium, resulting in muscle in-excitability and weakness. Patients typically present with episodic muscle weakness often triggered by high-carbohydrate meals, rest after exercise, or stress. The attacks are usually rapid in onset and can be life-threatening if respiratory muscles are involved. Diagnosis is suggested by clinical history and confirmed by laboratory tests showing hypokalemia during attacks. Differential diagnoses include thyrotoxic periodic paralysis (which requires thyroid evaluation) and hyperkalemic periodic paralysis (which is associated with high potassium levels during attacks). First-line treatment for an acute attack is potassium supplementation\u2014oral if the patient is able to swallow, or intravenous in severe cases. Acetazolamide and potassium-sparing diuretics (such as spironolactone) may be used for prophylaxis. Special considerations during pregnancy and lactation require careful monitoring of potassium levels and the use of medications that are considered safe in these populations, with consultation from maternal\u2013fetal medicine as necessary. Option a (Spironolactone) is a potassium-sparing diuretic that is useful in prophylaxis but not for acute reversal. Option b (Acetazolamide) helps prevent episodes but does not acutely reverse paralysis. Option c (Potassium) directly addresses the underlying hypokalemia, making it the correct treatment for an acute attack. 1. Rapid correction of hypokalemia with potassium is essential to abort the paralysis episode. 2. Be aware of the triggers for HypoPP attacks to advise appropriate lifestyle modifications. 3. Always consider thyrotoxicosis as an underlying contributor. Recent guidelines and studies continue to support the use of rapid potassium replacement during acute attacks of HypoPP, while acetazolamide remains a favored prophylactic agent in many patients. Ongoing research into genotype\u2013phenotype correlations may further refine management strategies.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "51-subacute flaccid quadriplegic post diarrheal illnesses sparing face & sensation",
    "option_a": "(AMAN) is most consistent with the clinical presentation described. Option b (GBS/AIDP) usually has demyelination with sensory involvement and often facial weakness. Option c (AMSAN) involves both motor and sensory fibers, and option d (CIDP) is characterized by a chronic course, making them less likely.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "Guillain\u2013Barr\u00e9 syndrome (GBS) has several variants. The acute motor axonal neuropathy (AMAN) variant is characterized by axonal damage affecting motor fibers while sparing sensory fibers. This variant is typically post-infectious, particularly following gastrointestinal illnesses. In AMAN, antibodies (often anti-ganglioside antibodies) target motor axons leading to acute axonal degeneration. Unlike the acute inflammatory demyelinating polyradiculoneuropathy (AIDP) variant, there is minimal or no demyelination, and sensory nerves remain intact. The patient\u2019s history of a diarrheal illness followed by subacute flaccid quadriplegia\u2014with sparing of facial muscles and sensation\u2014strongly suggests the AMAN variant. In contrast, AIDP often presents with demyelination accompanied by sensory changes and facial weakness. Electrophysiological studies are critical. In AMAN, nerve conduction studies reveal reduced compound muscle action potentials with preserved sensory responses. Differential diagnoses include AIDP (classical GBS), acute motor-sensory axonal neuropathy (AMSAN, which involves sensory fibers), and chronic inflammatory demyelinating polyneuropathy (CIDP), which has a more insidious onset. Management involves immunotherapy, typically with intravenous immunoglobulin (IVIG) or plasmapheresis. Supportive care, including respiratory monitoring and physical therapy, is critical. In pregnant or lactating patients, both IVIG and plasmapheresis are generally considered safe with proper monitoring, though decisions should be made in consultation with maternal\u2013fetal medicine. Option a (AMAN) is most consistent with the clinical presentation described. Option b (GBS/AIDP) usually has demyelination with sensory involvement and often facial weakness. Option c (AMSAN) involves both motor and sensory fibers, and option d (CIDP) is characterized by a chronic course, making them less likely. 1. AMAN is distinguished from AIDP by its pure motor involvement. 2. A recent diarrheal illness is a common antecedent for AMAN. 3. Early electrophysiological testing assists in distinguishing between variants of GBS. Current guidelines endorse early immunotherapy with IVIG or plasmapheresis for all forms of GBS, including AMAN. Recent studies have focused on biomarkers such as anti-ganglioside antibodies to further delineate GBS subtypes and prognosticate outcomes.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "New-born with macroglossia, hypotonia & myotonia",
    "option_a": "(alpha galactosidase deficiency) refers to Fabry disease, which presents with completely different systemic manifestations. Option b (glycogen phosphorylase deficiency) describes the enzyme defect in McArdle disease, not compatible with a neonatal presentation. Option c (phosphorylase) is nonspecific and again points to conditions seen later in life. Although the marked answer was b, the correct enzyme deficiency in Pompe disease is acid alpha",
    "option_b": "",
    "option_c": "",
    "option_d": "(acid alpha",
    "option_e": "",
    "correct_answer": "d",
    "subspecialty": "Neuromuscular",
    "explanation": "The clinical presentation of a newborn with macroglossia and hypotonia is most consistent with Pompe disease, a glycogen storage disorder. Pompe disease (glycogen storage disease type II) is caused by a deficiency of acid alpha-glucosidase (also known as acid maltase). It is important to recognize that while McArdle disease (glycogen phosphorylase deficiency) also affects muscle metabolism, it typically presents later in childhood or adulthood with exercise intolerance and does not manifest with neonatal hypotonia or macroglossia. Pompe disease results from a deficiency in acid alpha-glucosidase, leading to the accumulation of glycogen within lysosomes. This lysosomal glycogen buildup disrupts normal muscle cell function, leading to progressive muscle weakness, cardiomyopathy, and respiratory compromise. In contrast, glycogen phosphorylase deficiency (seen in McArdle disease) impairs glycogenolysis in muscle, causing exercise-induced muscle cramps and myoglobinuria later in life. In the infantile form of Pompe disease, hallmark features include generalized hypotonia (a 'floppy baby'), macroglossia, feeding difficulties, and often cardiomegaly. The mention of myotonia in the question is atypical for Pompe disease; however, the combination of macroglossia and hypotonia in a newborn clearly points away from disorders like McArdle disease. Congenital myotonic dystrophy is another consideration for neonatal myotonia, but it does not typically present with macroglossia. Diagnosis of Pompe disease involves demonstrating low acid alpha-glucosidase activity in blood or muscle tissue, followed by genetic testing for GAA gene mutations. Differential diagnoses include congenital myotonic dystrophy (which presents with facial diplegia and grip myotonia) and metabolic myopathies such as McArdle disease. A careful clinical and biochemical workup is necessary to differentiate these conditions. The mainstay of treatment for Pompe disease is enzyme replacement therapy (ERT) with recombinant human acid alpha-glucosidase (alglucosidase alfa), which should be initiated as early as possible to improve outcomes. Supportive care including nutritional support, cardiac monitoring, and physical therapy is also critical. In pregnant or lactating patients who are carriers or affected with a milder late-onset phenotype, the use of ERT requires careful assessment and multidisciplinary management but is generally considered after risk-benefit discussion. Option a (alpha galactosidase deficiency) refers to Fabry disease, which presents with completely different systemic manifestations. Option b (glycogen phosphorylase deficiency) describes the enzyme defect in McArdle disease, not compatible with a neonatal presentation. Option c (phosphorylase) is nonspecific and again points to conditions seen later in life. Although the marked answer was b, the correct enzyme deficiency in Pompe disease is acid alpha-glucosidase; therefore, if an option d (acid alpha-glucosidase) were provided, it would be correct. 1. Pompe disease (GSD II) should be suspected in infants with hypotonia, macroglossia, and cardiomyopathy. 2. Acid alpha-glucosidase deficiency is the hallmark of Pompe disease, not glycogen phosphorylase deficiency. 3. Early initiation of enzyme replacement therapy is critical for improving outcomes. Recent studies and updated guidelines emphasize early diagnosis of Pompe disease via newborn screening programs. Enzyme replacement therapy has been shown to improve survival and cardiac function in the infantile form. Ongoing trials aim to optimize dosing and assess long-term benefits, and multidisciplinary approaches continue to be advocated for managing systemic complications in affected infants.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "2 days post-partum with flaccid paralysis, decrease reflexes with NL sensation",
    "option_a": "(NCS) is correct because it directly assesses peripheral nerve function and can identify demyelination or axonal injury early in the disease course. Option b (LP) is less sensitive early on as the classic albuminocytologic dissociation may develop after the first week. Option c (MRI cervical spine) is more suited to central causes, such as compressive myelopathy, which would show differing clinical signs including sensory level or upper motor neuron findings. Option d (Mg level) is not indicated as isolated electrolyte disturbances do not cause the isolated flaccid paralysis with preserved sensation seen in this case.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "a",
    "subspecialty": "Neuromuscular",
    "explanation": "This scenario describes a postpartum patient with acute onset flaccid paralysis, decreased reflexes, and preserved sensation \u2013 a classic presentation of an acute peripheral neuropathy such as Guillain\u2013Barr\u00e9 syndrome (GBS). Nerve conduction studies (NCS) are the mainstay initial diagnostic test to evaluate such neuromuscular failures. GBS is an immune-mediated disorder in which an aberrant immune response, often triggered by infections or immunologic shifts (which may include postpartum changes), causes demyelination and sometimes axonal damage in the peripheral nerves. NCS can detect slowed conduction velocities, conduction block, or reduced compound motor action potentials, which are hallmarks of the demyelinating process. Clinically, GBS presents with rapid progression of symmetric limb weakness, hyporeflexia or areflexia, and relatively intact sensation. In the postpartum period, hormonal and immunological changes might predispose to the onset of GBS. Given that lumbar puncture (LP) may not yet show the typical albuminocytologic dissociation early on, electrophysiological evaluation becomes critical. The primary differentials include acute inflammatory demyelinating polyradiculoneuropathy (GBS), electrolyte disturbances, and central causes such as compressive myelopathy or spinal cord ischemia. NCS helps distinguish peripheral demyelination from central lesions, which would typically show upper motor neuron signs and sensory level deficits. Once GBS is confirmed, first-line treatments include intravenous immunoglobulin (IVIG) or plasmapheresis, both of which are considered safe in the postpartum period. Supportive care (e.g., respiratory support if needed) and careful physical therapy are essential. For lactating mothers, these treatments are typically acceptable with appropriate monitoring and consultation with obstetrics. Option a (NCS) is correct because it directly assesses peripheral nerve function and can identify demyelination or axonal injury early in the disease course. Option b (LP) is less sensitive early on as the classic albuminocytologic dissociation may develop after the first week. Option c (MRI cervical spine) is more suited to central causes, such as compressive myelopathy, which would show differing clinical signs including sensory level or upper motor neuron findings. Option d (Mg level) is not indicated as isolated electrolyte disturbances do not cause the isolated flaccid paralysis with preserved sensation seen in this case. 1. Early NCS can detect electrophysiological abnormalities in suspected GBS even before LP findings become classic. 2. In postpartum patients, consider GBS in the differential when sudden flaccid paralysis develops despite preserved sensory function. Recent guidelines and studies emphasize the importance of early electrophysiological testing in suspected GBS due to the latency in CSF changes. The American Academy of Neurology supports the use of NCS as a key diagnostic modality in suspected cases.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Spasticity, weakness d/t baclofen, what to try next",
    "option_a": "(Botox) is more suitable for localized spasticity rather than generalized spasticity. Option b (Tizanidine) has a similar side",
    "option_b": "",
    "option_c": "(increasing the baclofen dose) would likely exacerbate weakness. Option d (Baclofen pump) is correct because intrathecal delivery reduces systemic side effects while effectively controlling spasticity.",
    "option_d": "",
    "option_e": "",
    "correct_answer": "d",
    "subspecialty": "Neuromuscular",
    "explanation": "Spasticity is an abnormal increase in muscle tone commonly seen in patients with upper motor neuron lesions. Oral baclofen is a first\u2010line agent; however, its systemic administration can lead to adverse effects such as weakness and sedation. Baclofen, a GABA-B receptor agonist, works by inhibiting excitatory neurotransmission in the spinal cord to reduce spasticity. When administered orally, high systemic concentrations may lead to generalized muscle weakness. The intrathecal baclofen pump delivers the drug directly into the cerebrospinal fluid, achieving effective concentrations at the level of the spinal cord while minimizing systemic exposure. In patients with widespread spasticity who develop unacceptable systemic side effects (for example, weakness) from oral baclofen, intrathecal delivery allows for better spasticity control with fewer adverse effects. This is especially important when spasticity hampers function and quality of life. Before considering pump therapy, it is important to confirm that the weakness is indeed medication\u2010induced and not from alternative neuromuscular or systemic pathologies. A detailed medication history and clinical examination help differentiate these causes. First-line management typically involves oral antispastic agents like baclofen, tizanidine, or benzodiazepines. When oral agents cause intolerable side effects, a second-line strategy is the intrathecal baclofen pump, which allows for lower effective doses with minimal systemic toxicity. In pregnancy, the use of any centrally acting muscle relaxants must be carefully weighed against maternal benefits and fetal risks; intrathecal therapy can sometimes be maintained with multidisciplinary team input, and lactation considerations also require careful management with neurology and obstetric consultation. Option a (Botox) is more suitable for localized spasticity rather than generalized spasticity. Option b (Tizanidine) has a similar side-effect profile to baclofen and might not alleviate weakness. Option c (increasing the baclofen dose) would likely exacerbate weakness. Option d (Baclofen pump) is correct because intrathecal delivery reduces systemic side effects while effectively controlling spasticity. 1. Intrathecal baclofen therapy is reserved for patients with refractory spasticity who cannot tolerate oral medications. 2. Direct CSF delivery minimizes systemic exposure and can reduce the weakness associated with oral baclofen. Recent studies and neurology guidelines support the use of intrathecal baclofen pumps in patients who experience significant systemic side effects from oral baclofen, highlighting improved functional outcomes and reduced side effects with targeted drug delivery.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Post radio 28 months (breast CA) 3rd-4th finger numbness & with arm\u2019s pain",
    "option_a": "(MRI) is not definitive in differentiating radiation",
    "option_b": "(CSF analysis) is generally not useful unless there is suspicion for leptomeningeal spread. Option c (Nerve Conduction Studies) is the best initial test as it objectively measures nerve function and localizes demyelination or axonal loss. Option d is not provided as a relevant diagnostic step in this context.",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "c",
    "subspecialty": "Neuromuscular",
    "explanation": "This patient, with a history of radiotherapy for breast cancer, now presents with numbness in the 3rd\u20134th fingers and arm pain, a pattern consistent with a brachial plexopathy. Nerve conduction studies (NCS) are key to evaluating such peripheral nerve dysfunction. Radiation can lead to progressive fibrosis and demyelination of the nerves comprising the brachial plexus. This damage can selectively affect the conduction properties of the affected nerves, which is detectable by NCS as evidence of demyelination or axonal loss. The distribution of numbness (often affecting the lower roots of the brachial plexus) and associated pain following radiotherapy point toward a radiation-induced brachial plexopathy rather than central or radicular causes. Sensory deficits with preserved motor strength, or vice versa, help in localizing the lesion. Differential diagnoses for post-radiation arm pain and numbness include cervical radiculopathy, metastatic disease, and radiation-induced brachial plexopathy. NCS distinguishes these conditions by evaluating nerve conduction across the brachial plexus. MRI can offer supplementary imaging but is less definitive in the presence of post-radiation changes. Management is largely symptomatic and supportive. Options include pain management with neuropathic agents, physical therapy, and sometimes nerve blocks. It is important to exclude tumor recurrence because management strategies for a neoplastic process differ considerably. In pregnancy or lactation, pain management should be tailored to avoid teratogenic or excretion risks, with a preference for agents with established safety profiles. Option a (MRI) is not definitive in differentiating radiation-induced changes from tumor infiltration. Option b (CSF analysis) is generally not useful unless there is suspicion for leptomeningeal spread. Option c (Nerve Conduction Studies) is the best initial test as it objectively measures nerve function and localizes demyelination or axonal loss. Option d is not provided as a relevant diagnostic step in this context. 1. In patients with a history of radiotherapy, new-onset upper limb neuropathic symptoms should raise suspicion for radiation-induced brachial plexopathy. 2. NCS is the diagnostic modality of choice to differentiate between radiation-induced changes and other causes like neoplastic involvement. Current research supports the role of electrophysiological studies as the primary diagnostic tool for radiation-induced brachial plexopathy, with MRI reserved for cases where there is a high index of suspicion for tumor recurrence.",
    "exam_year": "2019",
    "exam_type": "Part I"
  },
  {
    "question": "Dysautonomia + CTS, Dx:",
    "option_a": "(Protein electrophoresis) is correct as it detects monoclonal proteins and is a key initial screening test. Option b (Abdominal fat aspiration) is less sensitive as an initial test and is more confirmatory. Option c (EMG/NCS) can demonstrate neuropathy but does not help in identifying the underlying plasma cell dyscrasia. Option d (Immunofixation) is also correct because it is more sensitive than SPEP in detecting small monoclonal proteins; both tests, used together, provide comprehensive initial screening.",
    "option_b": "",
    "option_c": "",
    "option_d": "",
    "option_e": "",
    "correct_answer": "A and D",
    "subspecialty": "Neuromuscular",
    "explanation": "The combination of dysautonomia and carpal tunnel syndrome (CTS) in this context raises concern for an infiltrative systemic process such as AL (light-chain) amyloidosis, which is often associated with plasma cell dyscrasias. Screening for a monoclonal protein is essential in such cases. In AL amyloidosis, misfolded immunoglobulin light chains deposit in various tissues including peripheral nerves and connective tissues, leading to dysautonomia and even CTS. These deposits disrupt normal nerve and tissue function, explaining the clinical presentation. Patients with AL amyloidosis may present with a mixed picture of autonomic dysfunction (including orthostatic hypotension, gastrointestinal dysmotility) alongside compressive neuropathies like CTS. The presence of a monoclonal gammopathy (detected via protein electrophoresis or immunofixation) supports this diagnosis. Key differential diagnoses include diabetic neuropathy, idiopathic CTS, and other forms of systemic amyloidosis. Serum protein electrophoresis (SPEP) and immunofixation are utilized to detect and characterize monoclonal proteins; while abdominal fat aspiration for amyloid can be confirmatory, its sensitivity is variable and it is not a first-line screening test. Management involves treating the underlying plasma cell disorder \u2013 typically with chemotherapeutic agents like bortezomib, cyclophosphamide, and dexamethasone \u2013 to reduce light-chain production. Supportive management for CTS may include splinting or surgery, and autonomic symptoms are managed symptomatically. In pregnant or lactating patients, the use of chemotherapy is particularly challenging and requires a multidisciplinary approach to balance maternal treatment with fetal/neonatal risks. Option a (Protein electrophoresis) is correct as it detects monoclonal proteins and is a key initial screening test. Option b (Abdominal fat aspiration) is less sensitive as an initial test and is more confirmatory. Option c (EMG/NCS) can demonstrate neuropathy but does not help in identifying the underlying plasma cell dyscrasia. Option d (Immunofixation) is also correct because it is more sensitive than SPEP in detecting small monoclonal proteins; both tests, used together, provide comprehensive initial screening. 1. In patients presenting with dysautonomia and CTS, always consider systemic amyloidosis as a potential underlying cause. 2. A combination of serum protein electrophoresis and immunofixation is recommended for the sensitive detection of a monoclonal gammopathy. Recent guidelines underscore the importance of immunofixation along with SPEP for diagnosing AL amyloidosis, as modern immunofixation techniques have improved sensitivity for detecting small monoclonal protein spikes that might be missed with SPEP alone.",
    "exam_year": "2019",
    "exam_type": "Part I"
  }
]